7210 Wareham Drive, Tampa, FL 33647
Nov. 6, 2025 Weight loss products are a major part of Herbalife’s business, accounting for 55% of total sales for the first nine months of 2025. According to Stephan Gratziani, CEO,… “Herbalife’s third-quarter performance reflects continued progress in our transformation strategy, as well as disciplined financial and operational execution. With North America returning to growth […]
Herbalife Reports 3rd Qtr. Results Read More »
June 18, 2025 Following approval of its Plan of Reorganization, WW is on track to exit the court-supervised financial reorganization process as early as next week. “This is a meaningful turning point for WeightWatchers,” said Tara Comonte, CEO of Weight Watchers. “We’ve taken decisive action to significantly strengthen our financial foundation and will emerge with
Weight Watchers Reorganization Plan Confirmed Read More »
May 6, 2025 WW management reported first quarter 2025 results today. “We are making progress on our strategic priorities with continued momentum in our Clinical business, while laying the foundation for long-term, sustainable growth,” said Tara Comonte, President and CEO. “As the weight management landscape evolves, we believe our unique combination of science-backed behavioral support,
Weight Watchers Reports Q1 Results Read More »
April 12, 2025 We noticed a post on Instagram today that pitches a company that will set up a medical weight loss program, using GLP-1 drugs for gyms. We shouldn’t be surprised. Everyone else has entered the GLP-1 gold rush, including med spas, so why not gyms as well? The company offering this “opportunity” is
Gyms Start Selling GLP-1 Drugs? The Bandwagon Gets More Crowded Read More »
April 3, 2025 Premca Capital, an investment fund, has nominated three directors for election to WW International’s board, according to the people familiar with the matter. WW has a market capitalization of about $40 million, following a sharp decline in its shares in recent years. Its stock is down nearly 70% in the past year, due
Weight Watchers Investor Seeks Board Seats Read More »
March 31, 2025 Many economists and analysts are saying that a recession is coming sometime this year. That said, many weight loss companies and their top managers will say they’ll have to cut expenses, especially marketing. That’s the knee-jerk reaction, but it’s dead wrong. When consumers cut back on spending, they will revert to trusted
A Recession Is NOT The Time To Cut Marketing Read More »
October 17, 2024 According to State Health, the telehealth GLP-1 boom wouldn’t be possible without clinicians willing to write prescriptions for those hundreds of thousands of patients. Companies are rarely transparent — with patients or the public — about the medical groups behind the screens. But a STAT examination found that just a handful of networks of
Invisible Medical Groups Are Behind GLP-1 Boom Read More »
Sept. 23, 2024 According to Becker’s Hospital Review… On Sept. 24, Novo Nordisk CEO Lars Fruergaard Jørgensen is slated to testify at a Senate committee hearing about the costs for Wegovy and Ozempic. The hearing comes after months of disagreements between Denmark-based Novo Nordisk and the Senate Committee on Health, Education, Labor and Pensions. The
GLP-1 Drugs Market Update Read More »
Jan. 11, 2024 The pandemic had significant effects on the way commercial weight loss companies operate, along with the explosive demand for GLP-1 obesity drugs such as Ozempic, Wegovy, and Mounjaro. Marketdata estimates that between Medifast, Weight Watchers, Jenny Craig, and Noom, at least 26,500 weight loss coaches have lost their jobs since 2020. Here’s
Ozempic Boom Is Hurting Weight Loss Coaches Read More »
Feb. 3, 2022 As reported here and in many other publications, Noom’s rapid growth as a weight loss program is well known. The company may plan an IPO this year, and it’s estimated that revenues topped $600 million last year. The company has raised $669 million to date. However, there may be some weak spots.